CO2022010294A2 - Anticuerpos cd163 o proteinas de union - Google Patents
Anticuerpos cd163 o proteinas de unionInfo
- Publication number
- CO2022010294A2 CO2022010294A2 CONC2022/0010294A CO2022010294A CO2022010294A2 CO 2022010294 A2 CO2022010294 A2 CO 2022010294A2 CO 2022010294 A CO2022010294 A CO 2022010294A CO 2022010294 A2 CO2022010294 A2 CO 2022010294A2
- Authority
- CO
- Colombia
- Prior art keywords
- porcine
- antigen
- binds
- amino acid
- binding domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1919294.7A GB201919294D0 (en) | 2019-12-24 | 2019-12-24 | Antibodies or binding proteins |
| PCT/GB2020/053370 WO2021130502A1 (en) | 2019-12-24 | 2020-12-24 | Cd163 antibodies or binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022010294A2 true CO2022010294A2 (es) | 2022-10-31 |
Family
ID=69322779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0010294A CO2022010294A2 (es) | 2019-12-24 | 2022-07-21 | Anticuerpos cd163 o proteinas de union |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230203185A1 (enExample) |
| EP (1) | EP4081542A1 (enExample) |
| JP (1) | JP7702952B2 (enExample) |
| KR (2) | KR20260098023A (enExample) |
| CN (2) | CN115151569B (enExample) |
| BR (1) | BR112022012362A2 (enExample) |
| CL (1) | CL2022001706A1 (enExample) |
| CO (1) | CO2022010294A2 (enExample) |
| DO (2) | DOP2022000136A (enExample) |
| GB (1) | GB201919294D0 (enExample) |
| MX (1) | MX428622B (enExample) |
| PE (1) | PE20230384A1 (enExample) |
| WO (1) | WO2021130502A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12098400B2 (en) * | 2022-07-08 | 2024-09-24 | Novo Nordisk A/S | Highly potent ISVD compounds capable of substituting for FVIII(A) |
| GB202214979D0 (en) * | 2022-10-11 | 2022-11-23 | Eco Animal Health Ltd | Binding protein |
| JP2026519901A (ja) * | 2023-01-27 | 2026-06-19 | ヴィーアイビー ヴィーゼットヴィー | Ｃｄ１６３結合複合体 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| CN119569865B (zh) * | 2024-12-20 | 2025-10-10 | 西北农林科技大学 | 一种防治猪繁殖与呼吸障碍综合征病毒感染的混合制剂及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076501A2 (en) * | 2001-03-26 | 2002-10-03 | Hemosol Inc. | Blood cell production via activation of the hemoglobin scavenger receptor |
| NZ540194A (en) * | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US20160158368A1 (en) * | 2014-10-31 | 2016-06-09 | Therapure Biopharma Inc. | Methods and compositions for the treatment of histiocytosis |
| HRP20240908T1 (hr) * | 2015-08-06 | 2024-10-25 | The Curators Of The University Of Missouri | Svinja i stanice otporne na virus reproduktivnog i respiratornog sindroma svinja (prrsv) koje imaju modificirane cd163 gene |
| US11160260B2 (en) * | 2018-04-17 | 2021-11-02 | The Curators Of The University Of Missouri | Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV) |
-
2019
- 2019-12-24 GB GBGB1919294.7A patent/GB201919294D0/en not_active Ceased
-
2020
- 2020-12-24 WO PCT/GB2020/053370 patent/WO2021130502A1/en not_active Ceased
- 2020-12-24 MX MX2022007957A patent/MX428622B/es unknown
- 2020-12-24 CN CN202080097372.4A patent/CN115151569B/zh active Active
- 2020-12-24 US US17/788,539 patent/US20230203185A1/en active Pending
- 2020-12-24 CN CN202610134672.4A patent/CN121873247A/zh active Pending
- 2020-12-24 KR KR1020267019563A patent/KR20260098023A/ko active Pending
- 2020-12-24 EP EP20838276.2A patent/EP4081542A1/en active Pending
- 2020-12-24 PE PE2022001329A patent/PE20230384A1/es unknown
- 2020-12-24 BR BR112022012362A patent/BR112022012362A2/pt unknown
- 2020-12-24 JP JP2022539134A patent/JP7702952B2/ja active Active
- 2020-12-24 KR KR1020227025626A patent/KR20220119147A/ko not_active Ceased
-
2022
- 2022-06-20 CL CL2022001706A patent/CL2022001706A1/es unknown
- 2022-06-23 DO DO2022000136A patent/DOP2022000136A/es unknown
- 2022-07-21 CO CONC2022/0010294A patent/CO2022010294A2/es unknown
-
2025
- 2025-11-21 DO DO2025000290A patent/DOP2025000290A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023508674A (ja) | 2023-03-03 |
| US20230203185A1 (en) | 2023-06-29 |
| PE20230384A1 (es) | 2023-03-06 |
| CN115151569A (zh) | 2022-10-04 |
| KR20260098023A (ko) | 2026-06-25 |
| BR112022012362A2 (pt) | 2022-09-06 |
| CN121873247A (zh) | 2026-04-17 |
| MX2022007957A (es) | 2022-10-07 |
| WO2021130502A1 (en) | 2021-07-01 |
| CL2022001706A1 (es) | 2023-05-26 |
| DOP2022000136A (es) | 2022-11-30 |
| DOP2025000290A (es) | 2026-02-26 |
| KR20220119147A (ko) | 2022-08-26 |
| CA3162664A1 (en) | 2021-07-01 |
| MX428622B (es) | 2025-11-13 |
| CN115151569B (zh) | 2026-05-01 |
| EP4081542A1 (en) | 2022-11-02 |
| JP7702952B2 (ja) | 2025-07-04 |
| GB201919294D0 (en) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000136A (es) | Anticuerpos cd163 o proteínas de unión | |
| CR20210199A (es) | Moléculas de unión a antígeno capaces de unirse al cúmulo de diferenciación 3 (cd3) y al cúmulo de diferenciación 137 (cd137) pero no simultáneamente | |
| CR20200579A (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| AR109882A1 (es) | Anticuerpos monoclonales neutralizantes anti-tl1a | |
| IL299221A (en) | Cd3 binding antibodies | |
| DOP2023000130A (es) | ANTICUERPOS MULTIESPECÍFICOS QUE TIENEN ESPECIFICIDAD PARA IL-4R e IL-31 | |
| HRP20241381T1 (hr) | Nova anti-pd-1 protutijela | |
| UY37694A (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| PE20251579A1 (es) | Anticuerpos especificos para cd70 y sus usos | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| PE20141433A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| JP2015525795A5 (enExample) | ||
| PE20230839A1 (es) | Agentes de union a lair-1 y metodos para su uso | |
| PE20230306A1 (es) | Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| DOP2018000234A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| RU2009148597A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| EA201792329A1 (ru) | Способ мономеризации рекомбинантных молекул антител | |
| IL250289B2 (en) | Antibodies against angiopoietin-like 4 and methods of use | |
| WO2020257789A3 (en) | Anti-tim-3 antibodies | |
| AR087485A1 (es) | Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc | |
| MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
| BR112022006364A2 (pt) | Anticorpo híbrido | |
| BR112022011323A2 (pt) | Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos | |
| EA201991510A1 (ru) | Каркасы антител для снижения агрегирования полиспецифических антител |